Related references
Note: Only part of the references are listed.The complex interplay between autophagy and cell death pathways
Christina Ploumi et al.
BIOCHEMICAL JOURNAL (2022)
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
Marina Elena Cazzaniga et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
F. F. Pepe et al.
BMC CANCER (2022)
FAK Regulates VEGFR2 Expression and Promotes Angiogenesis in Triple-Negative Breast Cancer
Jun-Ping Shiau et al.
BIOMEDICINES (2021)
Metronomic Chemotherapy
Marina Elena Cazzaniga et al.
CANCERS (2021)
Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
Raluca Ioana Teleanu et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Autophagy modulation altered differentiation capacity of CD146+ cells toward endothelial cells, pericytes, and cardiomyocytes
Mehdi Hassanpour et al.
STEM CELL RESEARCH & THERAPY (2020)
Vessel co-option in cancer
Elizabeth A. Kuczynski et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
Cem Simsek et al.
JOURNAL OF ONCOLOGY (2019)
Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion
Raquel Munoz et al.
PLOS ONE (2019)
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
M. E. Cazzaniga et al.
BREAST (2019)
FAK is Required for Tumor Metastasis-Related Fluid Microenvironment in Triple-Negative Breast Cancer
Mei-Ren Pan et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Role of Matrix Metalloproteinases in Angiogenesis and Cancer
Saray Quintero-Fabian et al.
FRONTIERS IN ONCOLOGY (2019)
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
Efrat T. Harel et al.
ANTIBODIES (2019)
Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer
M. Martin et al.
CANCER RESEARCH (2019)
Macrophage Colony-stimulating Factor Mediates the Recruitment of Macrophages in Triple negative Breast Cancer
Xiaoqing Lu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
Metronomic combination of vinorelbine and 5Fluorouracil inhibit triple-negative breast cancer cells results from the proof-of-concept VICTOR-0 study
Maria Grazia Cerrito et al.
Oncotarget (2018)
Nuclear FAK and its kinase activity regulate VEGFR2 transcription in angiogenesis of adult mice
Shaogang Sun et al.
SCIENTIFIC REPORTS (2018)
Metastatic and triple-negative breast cancer: challenges and treatment options
Sumayah Al-Mahmood et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2018)
Conditioned medium mimicking the tumor microenvironment augments chemotherapeutic resistance via ataxia-telangiectasia mutated and nuclear factor-κB pathways in gastric cancer cells
Xinguo Zhuang et al.
ONCOLOGY REPORTS (2018)
Distinct role of autophagy on angiogenesis: highlights on the effect of autophagy in endothelial lineage and progenitor cells
Mehdi Hassanpour et al.
STEM CELL RESEARCH & THERAPY (2018)
Tumor microenvironment and therapeutic response
Ting Wu et al.
CANCER LETTERS (2017)
Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives
Kim C. Aalders et al.
CANCER TREATMENT REVIEWS (2017)
Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells
Eirini Biziota et al.
ANTI-CANCER DRUGS (2016)
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study
M. E. Cazzaniga et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
In Vitro Co-Culture Models of Breast Cancer Metastatic Progression towards Bone
Chiara Arrigoni et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance
Irina Kareva et al.
CANCER LETTERS (2015)
Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells
Myriam Catalano et al.
MOLECULAR ONCOLOGY (2015)
FAK signaling in human cancer as a target for therapeutics
Brian Y. Lee et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Clinical and molecular complexity of breast cancer metastases
Siker Kimbung et al.
SEMINARS IN CANCER BIOLOGY (2015)
Cancer metastases: challenges and opportunities
Xiangming Guan
ACTA PHARMACEUTICA SINICA B (2015)
Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12
Manja Wobus et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Src contributes to IL6-induced vascular endothelial growth factor-C expression in lymphatic endothelial cells
Yu-Han Huang et al.
ANGIOGENESIS (2014)
High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype
Vita M. Golubovskaya et al.
BMC CANCER (2014)
Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials
Elham Fakhrejahani et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2014)
Low-dose metronomic chemotherapy: A systematic literature analysis
K. Lien et al.
EUROPEAN JOURNAL OF CANCER (2013)
Metronomic Ceramide Analogs Inhibit Angiogenesis in Pancreatic Cancer through Up-regulation of Caveolin-1 and Thrombospondin-1 and Down-regulation of Cyclin D1
Guido Bocci et al.
NEOPLASIA (2012)
Update on triple-negative breast cancer: prognosis and management strategies
Olivier Brouckaert et al.
INTERNATIONAL JOURNAL OF WOMENS HEALTH (2012)
Triple-Negative Breast Cancer: Clinical and Histological Correlations
Zeinab Elsawaf et al.
BREAST CARE (2011)
Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma
Jeong Won Jang et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2011)
Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?
Nicolas Andre et al.
FUTURE ONCOLOGY (2011)
A Perspective on Cancer Cell Metastasis
Christine L. Chaffer et al.
SCIENCE (2011)
Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies
Vito Lorusso et al.
BREAST (2010)
Metronomic chemotherapy: new rationale for new directions
Eddy Pasquier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
B. K. Linderholm et al.
ANNALS OF ONCOLOGY (2009)
Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2009)
METRONOMIC CHEMOTHERAPY. CHANGING THE PARADIGM THAT MORE IS BETTER
O.Graciela Scharovsky et al.
Current Oncology (2009)
Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player
Roberto Benelli et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation
Xuerong Wang et al.
CANCER RESEARCH (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Jie Ma et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition
Katherine Holmes et al.
CELLULAR SIGNALLING (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors
S. K. Mitra et al.
ONCOGENE (2006)
Capecitabine/vinorelbine:: An effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer
Franco Nole et al.
CLINICAL BREAST CANCER (2006)
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer:: antitumor activity and biological effects
M Colleoni et al.
ANNALS OF ONCOLOGY (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Angiogenesis in life, disease and medicine
P Carmeliet
NATURE (2005)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
Role of angiogenesis in tumor growth and metastasis
J Folkman
SEMINARS IN ONCOLOGY (2002)
The role of the microenvironment and intercellular cross-talk in tumor angiogenesis
SA Ahmad et al.
SEMINARS IN CANCER BIOLOGY (2002)
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
M Colleoni et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
